FFO
OTLK icon

Fortitude Family Office’s Outlook Therapeutics OTLK Stock Holding History

Fortitude Family Office’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$526 Buy
2,554
+2,130
+502% +$920 ﹤0.01% 1709
2025
Q4 		$670 Buy
+424
New +$677 ﹤0.01% 1606

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Fortitude Family Office's OTLK Position: Q1 2026 in Review

Fortitude Family Office increased its Outlook Therapeutics (OTLK) stake by 502% in Q1 2026, buying an estimated $920 and bringing the position to 2,554 shares worth $526. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

Fortitude Family Office first reported a position in OTLK in Q4 2025 and has held it in 2 quarters since. The position peaked at $670 in Q4 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Fortitude Family Office held 2,554 shares of Outlook Therapeutics worth $526 as of Q1 2026.
  • Fortitude Family Office bought 2,130 Outlook Therapeutics shares in Q1 2026, an estimated $920.
  • Outlook Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1709 holding.
  • Fortitude Family Office first reported a position in Outlook Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Fortitude Family Office's Outlook Therapeutics position peaked at $670 in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.